Table 1 Summary clinical information
| Â | Control subjects | SSc patients |
|---|---|---|
(N = 6) | (N = 23) | |
Age, median (range) years | 53 (25–67) | 53 (27–77) |
Sex, N (%) female | 4 (67%) | 19 (83%) |
Race, N (%) Caucasian | 5 (83%) | 20 (87%) |
SSc subtype, N (%) diffuse | NA | 15 (65%) |
MRSS, median (range) | NA | 16 (0–44) |
Disease duration from first non-Raynaud’s, median (range) years | NA | 1.0 (0–35) |
ILD/PAH, N (%) | NA | 8 (35%) |
ANA primary pattern, N (%) patients | ||
 Homogenous | NA | 1 (4%) |
 Nucleolar | NA | 5 (22%) |
 Speckled | NA | 6 (26%) |
 Centromere | NA | 2 (9%) |
SSc-specific antibodies, N (%) | ||
 Anti-centromere | NA | 3 (13%) |
 Scl-70 | NA | 3 (13%) |
 RNA polymerase III | NA | 5 (22%) |
 Current therapies, N (%) | NA | 17 (74%) |
Prior therapies, N (%) | ||
 Amlodipine | NA | 4 (17%) |
 Methotrexate | NA | 4 (17%) |
 Prednisone | NA | 3 (13%) |